(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 October 2025 (23.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/219911 A1

(51) International Patent Classification:
A61K 38/12 (2006.01) *A61P 37/00* (2006.01)
A61K 47/50 (2017.01) *A61P 39/00* (2006.01)
A61P 35/00 (2006.01) *C07K 16/00* (2006.01)

(21) International Application Number:
PCT/IB2025/054013

(22) International Filing Date:
16 April 2025 (16.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/634,719 16 April 2024 (16.04.2024) US
63/721,522 17 November 2024 (17.11.2024) US

(71) Applicant: **BIOHAVEN THERAPEUTICS LTD.** [US/GB]; P.O. Box 173, Kingston Chambers, Road Town, Tortola 1110 (VG).

(72) Inventors: **BUNIN, Anna**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **DIERKS, Elizabeth A.**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **CROCE, Kathren**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **KAZMIERSKI, Wieslaw**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **CORIC, Vladimir**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US). **CAR, Bruce D.**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US).

(74) Agent: **ZUEV, Dmitry**; Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, Connecticut 06510 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

WO 2025/219911 A1

(54) Title: TREATMENT OF DISEASES WITH MONOCLONAL ANTIBODY DRUGS AND MOLECULAR DEGRADERS

(57) Abstract: A method of treating a disease or a condition in a patient in need thereof includes administering to the patient an immunoglobulin G degrader and a monoclonal antibody drug, wherein the immunoglobulin G degrader is effective to bind to an anti-drug antibody induced by the monoclonal antibody drug. A method of restoring a therapeutic activity of a monoclonal antibody drug in a patient includes administering to the patient a therapeutically effective amount of an immunoglobulin G degrader, wherein the immunoglobulin G degrader is effective to bind to an anti-drug antibody induced by the monoclonal antibody drug.